MW : Glaxo reports positive Phase 2 PHN drug study
GlaxoSmithKline (GSK 38.72, -0.03, -0.08%) (UK:GSK 1,207, -11.50, -0.94%) and XenoPort (XNPT 19.83, -0.90, -4.34%) said a Phase II trial evaluating GSK1838262/XP13512 in adult patients with neuropathic pain associated with post-herpetic neuralgia demonstrated a statistically significant improvement over 1200 mg/day of GSK1838262 on the primary endpoint, which was the change from baseline to the end of the treatment period in the 24-hour average pain intensity score. The patients the companies tested the drug on previously had a history of inadequate response to gabapentin doses of 1800 mg/day or higher
